1. Scrip
  2. >>Business
  3. >>Strategy

Mineralys Seeks First-To-Market Edge In Uncontrolled Hypertension

 
• By Joseph Haas

Battling AstraZeneca in the aldosterone inhibitor space, Mineralys reports Phase III data showing lorundrostat can significantly decrease uncontrolled/resistant blood pressure at six weeks.

Gloved hand holding a blood pressure meter, indicating high blood pressure
Mineralys shows its aldosterone inhibitor can benefit patients with uncontrolled hypertension • Source: Alamy

Mineralys reported data from a pair of clinical trials for lorundrostat (MLS-101) in uncontrolled or resistant hypertension on 10 March that it asserts could provide a new treatment option for about 10 million underserved high blood pressure patients in the US. The Radnor, PA-based firm said its selective aldosterone synthase inhibitor should be ready to file for approval at the US Food and Drug Administration with the latest study results.

Key Takeaways
  • Mineralys reports data from two studies showing that its aldosterone inhibitor can offer blood pressure-reducing benefit in uncontrolled or resistant cases.

Clinical-stage Mineralys is engaged in a tight, head-to-head battle with AstraZeneca to bring the first aldosterone inhibitor to market in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

 
• By Jessica Merrill

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.

Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

 
• By Joseph Haas

Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.

More from Therapy Areas

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

 
• By Jessica Merrill

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.

Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

 
• By Joseph Haas

Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.

Nuvation Set For First Launch With Ibtrozi In Lung Cancer

 
• By Jessica Merrill

The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.